Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome
Brain Communications · 02.07.2024 · 6 (4)
DOI: 10.1093/braincomms/fcae183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Communications, online erschienen am 17.07.2024. Verfasst von Nick Corriveau-Lecavalier und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institutes of Health, Robert Wood Johnson Foundation.
Abstract (Originalsprache)
Predominant limbic degeneration has been associated with various underlying aetiologies and an older age, predominant impairment of episodic memory and slow clinical progression. However, the neurological syndrome associated with predominant limbic degeneration is not defined. This endeavour is critical to distinguish such a syndrome from those originating from neocortical degeneration, which may differ in underlying aetiology, disease course and therapeutic needs. We propose a set of clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome that is highly associated with limbic-predominant age-related TDP-43 encephalopathy but also other pathologic entities. The criteria incorporate core, standard and advanced features, including older age at evaluation, mild clinical syndrome, disproportionate hippocampal atrophy, impaired semantic memory, limbic hypometabolism, absence of neocortical degeneration and low likelihood of neocortical tau, with degrees of certainty (highest, high, moderate and low). We operationalized this set of criteria using clinical, imaging and biomarker data to validate its associations with clinical and pathologic outcomes. We screened autopsied patients from Mayo Clinic and Alzheimer’s Disease Neuroimaging Initiative cohorts and applied the criteria to those with an antemortem predominant amnestic syndrome (Mayo, n = 165; Alzheimer’s Disease Neuroimaging Initiative, n = 53) and who had Alzheimer’s disease neuropathological change, limbic-predominant age-related TDP-43 encephalopathy or both pathologies at autopsy. These neuropathology-defined groups accounted for 35, 37 and 4% of cases in the Mayo cohort, respectively, and 30, 22 and 9% of cases in the Alzheimer’s Disease Neuroimaging Initiative cohort, respectively. The criteria effectively categorized these cases, with Alzheimer’s disease having the lowest likelihoods, limbic-predominant age-related TDP-43 encephalopathy patients having the highest likelihoods and patients with both pathologies having intermediate likelihoods. A logistic regression using the criteria features as predictors of TDP-43 achieved a balanced accuracy of 74.6% in the Mayo cohort, and out-of-sample predictions in an external cohort achieved a balanced accuracy of 73.3%. Patients with high likelihoods had a milder and slower clinical course and more severe temporo-limbic degeneration compared to those with low likelihoods. Stratifying patients with both Alzheimer’s disease neuropathological change and limbic-predominant age-related TDP-43 encephalopathy from the Mayo cohort according to their likelihoods revealed that those with higher likelihoods had more temporo-limbic degeneration and a slower rate of decline and those with lower likelihoods had more lateral temporo-parietal degeneration and a faster rate of decline. The implementation of criteria for a limbic-predominant amnestic neurodegenerative syndrome has implications to disambiguate the different aetiologies of progressive amnestic presentations in older age and guide diagnosis, prognosis, treatment and clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Neuroscience, Mayo Clinic, Jacksonville, FL 3224, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Pathology, University of Kentucky, Lexington, KY 40506, USA.
ORCID-Profile: Nick Corriveau-Lecavalier, Hugo Botha, Jonathan Graff-Radford, Melissa E Murray, Dennis W Dickson, Vijay K Ramanan, Bradley F Boeve, Michel J Grothe, David S Knopman, Clifford R Jack, David T Jones
Förderung
- NIA NIH HHS
- National Institutes of Health
- Robert Wood Johnson Foundation
- Elsie and Marvin Dekelboum Family Foundation
- Liston Family Foundation
- Edson Family
- Gerald A. and Henrietta Rauenhorst
- Foundation and the Foundation Dr. Corinne Schuler
Zitieren
APA
Corriveau-Lecavalier, N., Botha, H., Graff-Radford, J., Switzer, A. R., Przybelski, S. A., Wiste, H. J., Murray, M. E., Reichard, R. R., Dickson, D. W., Nguyen, A. T., Ramanan, V. K., McCarter, S. J., Boeve, B. F., Machulda, M. M., Fields, J. A., Stricker, N. H., Nelson, P. T., Grothe, M. J., Knopman, D. S., …, & Jones, D. T. (2024). Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome. Brain Communications, 6(4). https://doi.org/10.1093/braincomms/fcae183
Vancouver
Corriveau-Lecavalier N, Botha H, Graff-Radford J, Switzer AR, Przybelski SA, Wiste HJ, et al. Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome. Brain Communications. 2024;6(4). doi:10.1093/braincomms/fcae183
BibTeX
@article{CorriveauLecavalier2024,
author = {Corriveau-Lecavalier, Nick and Botha, Hugo and Graff-Radford, Jonathan and Switzer, Aaron R and Przybelski, Scott A and Wiste, Heather J and Murray, Melissa E and Reichard, Robert Ross and Dickson, Dennis W and Nguyen, Aivi T and Ramanan, Vijay K and McCarter, Stuart J and Boeve, Bradley F and Machulda, Mary M and Fields, Julie A and Stricker, Nikki H and Nelson, Peter T and Grothe, Michel J and Knopman, David S and Lowe, Val J and Petersen, Ronald C and Jack, Clifford R and Jones, David T},
title = {Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome},
journal = {Brain Communications},
year = {2024},
volume = {6},
number = {4},
doi = {10.1093/braincomms/fcae183}
}
EUVIMED